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ABSTRACT
Taenia solium is the most common parasitic infection of the central nervous system 
and it can cause parenchymal or extra-parenchymal lesions. Subarachnoid cysticercosis is a 
type of extra-parenchymal infection in which the prevalence is not known and racemose NC 
with cerebellar involvement has been rarely reported. The diagnosis is challenging because 
of its similarity to other infectious diseases or to subarachnoid involvement of systemic 
malignancies. Treatment usually requires cysticide drugs, however, there are no randomized 
studies concerning the anti-parasitic treatment in subarachnoid NC. We present a case of 
racemose NC in the cerebellar hemisphere to draw attention to this pathology, endemic in 
many parts of the world; and highlight all the current gaps in our understanding of this entity. 
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INTRODUCTION 
Neurocysticercosis (NC) is the most common parasitic disease of the central 
nervous system (CNS) worldwide. Cysticercosis is endemic in most Latin American 
countries, large regions of Asia including the Indian subcontinent, most of Southeast 
Asia and China, sub-Saharan Africa, and some countries of Eastern Europe1, with 
most cases coming from rural areas and with an overall prevalence of 8.55% in 
Colombia1-5. After accidental ingestion of Taenia solium eggs (oncospheres), 
cysticerci hatch in the small intestine, penetrate into the intestinal wall and spread 
to other tissues through the bloodstream4. Although the majority of parasites are 
destroyed by the immune system, some can reach the CNS and allude the host’s 
immune response in part due to the protection offered by the blood-brain barrier. 
Once in the CNS, they can develop to the larval stage. An inflammatory response 
usually occurs which is more intense after the larval degeneration1-4.
NC is subdivided by its location into parenchymal or extra-parenchymal forms, 
the latter being the less frequent. Extra-parenchymal neurocysticercosis involves 
infection of the subarachnoid space, the spinal cord (except in the rare case of 
intramedullary NC) or the ventricular system3,5,6. The prevalence of subarachnoid 
NC is not known, and high variability exists in the few studies in the literature7. 
In addition, racemose NC with cerebellar involvement has been rarely reported8,9. 
We present a case of racemose NC in the cerebellar hemisphere to draw attention 
to this pathology, endemic in many parts of the world; and highlight all the current 
gaps in our understanding of this entity.
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CASE REPORT 
A 51-year-old male patient, who lives in a rural area, was 
first taken to the emergency department of another hospital 
with a 3-month history of headaches associated with gait 
alterations due to weakness of the lower limbs, instability, 
difficulty to climb stairs without support, memory loss and 
behavioral changes. The initial computed tomography (CT) 
of the head, according to his medical record and the radiology 
report, did not reveal any evident lesion and a lumbar 
puncture was performed showing hyperproteinorrachia, 
hypoglycorrhachia and mild lymphocytic pleocytosis. 
However, fungal and bacterial cultures, cryptococcus 
latex agglutination test, Mycobacterium tuberculosis (MT) 
polymerase chain reaction and MT culture were negative. 
Due to the lymphocytic pleocytosis and the high prevalence 
of tuberculosis in our country, empiric anti-tuberculosis 
treatment was started.
Nevertheless, the patient was evaluated again three 
months after his initial visit due to the persistence 
of symptoms and the onset of urinary incontinence, 
drowsiness, emesis and fever. The physical examination 
revealed that the patient was disoriented in time and 
space and had short-term memory difficulties. Acalculia 
was noticed. The examination of the eye fundus revealed 
bilateral papilledema without any other pathological 
finding. Physical examination did not reveal tremors 
or asymmetric pronation of hands. Rapid alternating 
movements and finger-to-nose movements were normal. 
However, the pull test was positive, and an ataxic gait was 
noticed. Meningeal signs were absent. Blood tests were 
carried out showing leukocytosis and neutrophilia without 
eosinophilia and a new lumbar puncture was performed 
with similar results to the previous, once again, all the 
infectious diseases investigations were negative. Due to 
the lack of response to the initial treatment, the diagnosis 
of meningeal tuberculosis was ruled out and treatment was 
suspended. Serological tests for Histoplasma, Cryptococcus 
and Aspergillus were negative. 
A head CT scan revealed ventricular dilation and the 
presence of a cerebellar cyst (Figure 1); the magnetic 
resonance imaging (MRI) of the brain showed a left 
cerebellar cyst along with severe dilation of the ventricular 
system compatible with hydrocephalus (Figure 2), so 
that a ventriculoperitoneal shunt was performed. Due 
to the clinical deterioration of the patient and the lack 
of a clear diagnosis, a biopsy of the cyst was performed 
with evidence of a cysticercus cyst (Figure 3). Racemose 
neurocysticercosis with cerebellar involvement was 
considered and 8 mg of intravenous dexamethasone every 
8 h in conjunction with albendazole at the maximum 
dose (30 mg/kg/day/) was started, as Praziquantel is not 
commercially available in Colombia. While hospitalized, 
the patient evolved with a progressive improvement of 
symptoms with subsequent discharge from the hospital. 
However, the follow-up visits were scheduled in another 
institution, and the patient was lost to follow up.
DISCUSSION 
Cysticerci are small vesicles that consist of the vesicular 
walls and the scolex. However, in some cysticercus the 
scolex cannot be identified because these parasites are 
composed of membranes attached to each other that tend 
to group in clusters resembling grapes. This form is called 
the racemose form of cysticerci and is observed in parasites 
located within the cerebrospinal fluid (CSF) cisterns at the 
base of the brain as the case of our patient10.
Figure 1 - Head CT. Severe dilation of the ventricular system, involving the third ventricle and lateral ventricles with transependymal 
edema and a multicystic lesion located in the subarachnoid space at the level of the lateral surface of the left cerebellar hemisphere.
Figure 2 - Axial Magnetic Resonance imaging of the brain. Flair 
(left) and T1 contrast (right) images with a multicystic lesion 
located in the subarachnoid space at the level of the lateral 
surface of the left cerebellar hemisphere. Note the absence of 
a scolex and the “mass effect”.
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Subarachnoid NC has a poor prognosis and a high 
mortality rate ranging from 20% to 50%7,8 in part due to 
the risk of developing cysts that can obstruct the drainage 
of cerebrospinal fluid leading to a high intracranial pressure 
and, if severe enough, subsequent hydrocephaly will take 
place possibly leading to death7,11. In the case presented 
here, a ventriculoperitoneal shunt was performed to prevent 
further complications.
Our patient was taken to the emergency room due to 
headaches, gait alterations and memory loss with behavioral 
changes; nevertheless, the clinical course is often varied 
depending on the location and the size of the cyst, but tends 
to be chronic in nature4,7. Intracranial hypertension can be 
found in 75% of the cases and manifests as headaches in 
almost 50% of the patients, cognitive impairment is seen 
in up to 21% of the cases, but the prevalence of cerebellar 
symptoms is not known due the scarcity of cases reported 
in the literature8,9. Furthermore, these symptoms are not 
specific which makes the diagnosis difficult and implies a 
challenge for the clinician7,11.
Radiologic studies such as CT or MRI are useful for 
diagnosis, classification and treatment monitoring in NC3. 
Nevertheless, there is no direct correlation between the 
presence of intracranial lesions in radiological studies 
and the clinical presentation, delaying the diagnosis4. 
The most common finding is hydrocephalus caused 
by an inflammatory occlusion secondary to a fibrous 
arachnoiditis. Cystic subarachnoid lesions may be small 
or reach a large size if they are located within the basal 
CSF cisterns where they usually have a multilobulated 
appearance behaving as a mass growing lesion as in our 
case10. However, subarachnoid NC represents an entity 
with a difficult radiological diagnosis compared to its 
parenchymal counterpart because parasites emit a signal 
similar to the one of the cerebrospinal fluid in MRI which 
limits their visualization11,12. In addition, in the racemose 
form, the scolex cannot be identified. The mechanism 
responsible is not well understood, but the disappearance 
of the scolex in the racemose form could be secondary to 
a degenerative process called hydropic degeneration, that 
in turn will favor the continuous entrance of CSF inside 
the vesicle10. Racemose neurocysticercosis with cerebellar 
involvement has been rarely reported probably as a result 
of a reduced blood flow in comparison with the cerebrum8.
Concerning the serological diagnosis, tests with enzyme-
linked immunoelectrotransfer blot (EITB) are recommended 
as a confirmatory test, with 100% specificity and 50-98% 
sensitivity. However, EITB is not widely available, and a 
positive result is not necessarily pathognomonic of NC. 
On the other hand, the detection of antigens by Enzyme-
linked immunosorbent assay (ELISA) is not recommended 
due to its low sensitivity and specificity13. For this reason, 
EITB is the most useful laboratory tool when there is an 
unclear diagnosis13. In this case, the test was available and 
was performed during the patient’s second visit. However, 
while waiting for the results, a clinical deterioration forced 
a brain biopsy. 
Diagnosis of subarachnoid NC via CSF analysis can 
be challenging because of its similarity to other infectious 
diseases, like tuberculosis or subarachnoid involvement of 
systemic malignancies that may have comparable clinical 
and imaging findings14,15. To help in the diagnosis of NC, 
Del Brutto10 established the new diagnostic criteria based 
on imaging studies and clinical findings.
Cysticide drugs have been used in subarachnoid NC 
since 1990 and subsequent non-controlled studies reported 
Figure 3 - Hematoxylin-Eosin staining of a biopsy specimen from the cerebellar cyst: A) Upper left image. Outer edge of the cyst 
containing an intense inflammatory infiltrate. Larger image. Wall of a cysticercus cyst in small magnification (2.52 x); B) Wall of a 
cysticercus cyst with cuticular (1), cellular (2), and reticular (3) layer (12.6 x). The cuticular layer shows small, villous protrusions, 
the cellular layer is located just below the cuticular layer, and the reticular layer is the larger one, containing a loosely arranged 
matrix, and excretory canaliculi.
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the efficacy of albendazole for destroying subarachnoid 
cysticercus. However, there are important differences in the 
dose used, the duration, and the use of combined therapy 
with praziquantel16. Nevertheless, the 2017 Clinical Practice 
Guidelines by the Infectious Diseases Society of America 
recommends the use of Albendazole (15 mg/kg/day) in 
combination with Praziquantel13 but in many countries such 
as Colombia, Praziquantel is not commercially available, 
and an alternative therapeutic approach is needed due 
to the risk of therapeutic failure. To date there are only 
two studies that compared the usual dose of albendazole 
(15 mg/kg/day) with a higher dose (30 mg/kg/day), showing 
promising results, unfortunately, both studies were small, 
and the treatment duration was heterogenous17,18. In our 
patient an immediate clinical improvement seemed to be 
an indicator of adequate tolerance, unfortunately the patient 
was lost to follow-up. 
It is important to mention that there are also case reports 
of the parasite persistence despite the use of albendazole. 
This could be in part due to cysticide drugs differentially 
affecting the parasites according to their development 
stage, i.e., the lesser the penetration in the subarachnoid 
space, the higher the variability of plasma and CSF levels 
due to individual differences in the bioavailability. The 
use of corticosteroids could act as a key component of the 
immunological control of the infection19. Before initiating 
the therapy, the management of intracranial hypertension 
and hydrocephalus is recommended due to the risk of 
worsening of the intracranial hypertension with the use 
of cysticide drugs13. Surgical management is limited to 
the patients in whom medical treatment is not effective or 
feasible13,20.
To our knowledge, treatment for subarachnoid NC has 
not yet been clearly been established and the duration of 
the treatment is not known13,16.
CONCLUSION
This case report highlights the diagnostic challenges 
that subarachnoid NC represents and the gaps in knowledge 
regarding the optimum way to treat these patients. In 
countries with high prevalence of cysticercosis, like 
Colombia, it is important to include this entity in the 
differential diagnosis of chronic meningitis and cystic 
lesions in the cerebellum. This case should encourage the 
design of clinical studies to address important questions 
about the true epidemiology of this entity, the clinical 
features that could help in its prompt identification and 
the best therapeutic strategies. For an endemic disease in 
many South American countries, there is much we still do 
not know.
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